세계의 멀티오믹스 시장 규모, 점유율, 산업 동향 분석 리포트 : 유형별, 제품 및 서비스별, 최종 용도별, 플랫폼별, 용도별, 지역별 전망과 예측(2023-2030년)

The Global Multiomics Market size is expected to reach $5.7 billion by 2030, rising at a market growth of 15.0% CAGR during the forecast period.

Metabolomics aids is understanding how individuals metabolize drugs, which is critical for precision medicine. Thus, Metabolomics segment acquired $215 million in 2022. It can predict drug responses and identify potential adverse reactions, leading to optimized therapeutic strategies. Therefore, these factors will propel the expansion of the metabolomics segment in the upcoming years. Discovering biomarkers linked to many diseases, such as cancer, cardiovascular disease, diabetes, and neurological problems, has become much easier with metabolomics. The identification of disease-specific metabolites holds promise for early diagnosis and personalized treatment.

The major strategies followed by the market participants are Partnerships, Collaborations & Agreements as the key developmental strategy to keep pace with the changing demands of end users. For instance, In January, 2023, Bruker Corporation partnered with Biognosys AG. Under this partnership, both companies would create unique synergies between Biognosys' versatile offerings of proprietary proteomics services, software, and kits, and Bruker's pioneering timsTOF platform. Additionally, In November, 2022, BGI Group signed an agreement with the University of Pecs to launch a joint laboratory in Hungary. Additionally, this world-class facility would hasten the development of genomic sequencing and clinical diagnostic services.

Based on the Analysis presented in the KBV Cardinal matrix; Danaher Corporation and Thermo Fisher Scientific, Inc. are the forerunners in the Market. Companies such as Bruker Corporation, Illumina, Inc. and Becton Dickinson and Company are some of the key innovators in the Market. In January, 2022, Illumina, Inc. partnered with SomaLogic, a protein biomarker discovery and clinical diagnostics company. This partnership aimed to hasten the rapidly growing high throughput sector of the proteomics market.

Market Growth Factors

Rising advancements in high-throughput omics technologies

High-throughput omics technologies have substantially reduced the cost of data generation. This cost-effectiveness has democratized access to multiomics research, making it more affordable for a wider range of researchers, institutions, and companies. As a result, more players are entering the market, fostering innovation and competition. This level of granularity is critical for identifying potential biomarkers and therapeutic targets. The lowered barriers to entry have fostered a thriving ecosystem of start-ups and companies specializing in omics technologies and services. These factors are expected to boost the demand in the future.

Growing demand for personalized medicines worldwide

The emphasis on personalized medicine encourages healthcare providers and researchers to utilize multiomics technologies to a greater extent. This includes genomics, transcriptomics, proteomics, and metabolomics, which provide comprehensive insights into an individual's molecular and genetic makeup. This increased utilization leads to greater demand for multiomics services and solutions. Multiomics data can provide a detailed understanding of a patient's genetic predispositions, biomarker profiles, and disease risks. This integration boosts the demand for multiomics technologies and services. The demand for these data in personalized medicine has created opportunities for innovative start-ups and established companies to provide specialized services and technologies. Thus, these factors will drive the expansion of the market in the upcoming years.

Market Restraining Factors

Continually evolving regulatory environment of multiomics

Data sharing is vital for scientific collaboration and the advancement of multiomics research. However, the need to protect patient privacy and comply with regulations can limit the extent to which data can be shared. This may hinder collaborative research efforts and restrict the availability of multiomics datasets. Regulatory changes can be frequent and unpredictable. Organizations in this market must continuously monitor and adapt to evolving regulations, which can introduce uncertainty into their operations. Regulatory shifts can necessitate changes in data handling, research methodologies, and business models. These factors are expected to limit the growth of this market in the coming years.

Type Outlook

On the basis of type, the market is divided into single-cell multiomics and bulk multiomics. The bulk multiomics segment recorded the maximum revenue share in the market in 2022. The availability of sophisticated bioinformatics tools and data integration platforms has facilitated the analysis and interpretation of bulk multiomics data. Researchers can now perform cross-omics analyses with relative ease, identifying correlations and patterns across different data types. Bulk multiomics plays a pivotal role in the advancement of precision medicine. By analyzing an individual's multiomics profile, clinicians can tailor treatments to their unique molecular characteristics. This approach holds significant promise for improving patient outcomes and reducing adverse effects. Owing to these factors, there will be an increased demand in the bulk multiomics segment.

Product & Service Outlook

Based on product & service, the market is segmented into products and services. In 2022, the services segment garnered a significant revenue share in the market. The continued development of high-throughput omics technologies has made generating vast amounts of data possible. However, analyzing this data requires specialized expertise, leading to a greater reliance on services offered by dedicated providers. Multiomics data is inherently complex, with a multitude of variables and interactions. The interpretation of this data demands sophisticated bioinformatics and computational tools, creating a niche for service providers to offer data analysis and interpretation solutions. These factors are expected to propel the demand in the services segment.

Product Outlook

The product segment is further subdivided into instruments, consumables, and software. In 2022, the instruments subsegment procured the highest revenue share in the market. Next-generation sequencing (NGS) platforms have witnessed remarkable advancements in sequencing capacity, read length, and data quality. These improvements have led to increased adoption of NGS for genomics and transcriptomics studies. Mass spectrometry technology has become more sensitive and capable of analyzing a broader range of molecules. This has expanded its use in proteomics and metabolomics research.

End-use Outlook

On the basis of end-use, the market is divided into academic & research institutes, pharmaceutical & biotechnology companies, and others. The academic and research institutes segment recorded the maximum revenue share in the market in 2022. Academic and research institutes have benefited from the growing availability of research funding from government sources and private foundations. Funding agencies recognize the importance of multiomics research in advancing scientific knowledge and addressing complex health and environmental challenges. This increased funding has allowed academic and research institutions to expand their multiomics research initiatives.

Platform Outlook

Based on platform, the market is segmented into genomics, transcriptomics, proteomics, metabolomics, and integrated omics platforms. The proteomics segment procured a promising growth rate in the market in 2022. Proteomic platforms can determine the functions of proteins, which is crucial for understanding their roles in various biological processes. This information is valuable for basic research and applied sciences. Proteomic analysis can also help in identifying proteins that can serve as therapeutic targets. In industries such as biopharmaceuticals, proteomic platforms are used for quality control to ensure the consistency and safety of products.

Application Outlook

On the basis of application, the market is divided into cell biology, oncology, neurology, and immunology. The cell biology segment recorded the maximum revenue share in the multiomics market in 2022. Cell biology, in conjunction with multiomics, plays a crucial role in cancer research and precision oncology. Researchers can now profile the molecular alterations in cancer cells in unprecedented detail. This has led to the discovery of new drug targets, the development of targeted therapies, and the identification of resistance mechanisms. It also contributes to personalizing cancer treatment regimens, improving patient outcomes. Owing to these factors, the demand will rise in the segment.

Regional Outlook

By region, the market is segmented into North America, Europe, Asia Pacific, and LAMEA. The North America segment procured the highest revenue share in the market in 2022. North America boasts a robust and well-funded research ecosystem with leading universities, academic institutions, and research organizations at the forefront of multiomics studies. These institutions have been driving research, publishing groundbreaking findings, and attracting substantial research funding. Thus, there will be increased demand in the segment.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc, Illumina, Inc., Danaher Corporation, PerkinElmer, Inc., Bruker Corporation, Qiagen N.V., Agilent Technologies, Inc., BGI Group, Becton, Dickinson, and Company, Shimadzu Corporation

Recent Strategies Deployed in Multiomics Market

Partnerships, Collaborations & Agreements

Mar-2023: Illumina Inc. came into partnership with Myriad Genetics Inc., a leader in genetic testing and precision medicine. This partnership aimed to widen access to and availability of oncology homologous recombination deficiency testing in the United States.

Jan-2023: Bruker Corporation partnered with Biognosys AG, a Switzerland-based company. Under this partnership, both companies would create unique synergies between Biognosys' versatile offerings of proprietary proteomics services, software, and kits, and Bruker's pioneering timsTOF platform.

Nov-2022: BGI Group signed an agreement with the University of Pecs, the largest higher education institution in Hungary. This agreement aimed to launch a joint laboratory in Hungary. Additionally, this world-class facility would hasten the development of genomic sequencing and clinical diagnostic services, while empowering BGI Genomics and the UP's leadership in genomics, bioinformatics, reproductive health, and precision medicine in the Central and Eastern European region.

Oct-2022: Illumina Inc. collaborated with AstraZeneca, a global, science-led biopharmaceutical company. This collaboration aimed to hasten drug target discovery by integrating strengths in artificial intelligence-based genome interpretation and genomic analysis techniques along with industry expertise. Additionally, this collaboration would evaluate whether a combined framework of these technologies could increase the yield and confidence of target discovery to find promising drugs based on human omics insights.

Feb-2022: Agilent Technologies Inc. came into partnership with MRM Proteomics, Inc., a biotechnology company. This partnership would offer a complete solution for quantitative protein and metabolite analysis.

Jan-2022: Illumina, Inc. partnered with SomaLogic, a protein biomarker discovery and clinical diagnostics company. This partnership aimed to hasten the rapidly growing high throughput sector of the proteomics market.

Jan-2022: Illumina, Inc. signed an agreement with Nashville Biosciences, LLC, a wholly owned subsidiary of Vanderbilt University Medical Center. This agreement aimed to hasten medicines development through large-scale genomics and the establishment of a preeminent clinico-genomic resource.

Jun-2021: BGI Group collaborated with Champions Oncology, a leading global oncology data-driven solutions provider. This collaboration aimed to provide mass spectrometry-based proteomics and multiomics data analysis solutions.

Product Launches and Product Expansions

Sep-2023: Bruker Corporation introduced 4D-Proteomics, MALDI HiPLEX-IHC spatial tissue proteomics, 4D-Lipidomics and 4D-Metabolomics. The launched product would perform precise quantification of peptides and proteins present in 100s or 1000s samples by utilizing global retention time and collision cross-section prediction models.

Mar-2023: Illumina Inc. released the novel Illumina Complete Long Read technology, a high-performance, long-read, human whole-genome sequencing assay. The launched product would provide users access to both long- and short-read data on the same Illumina instrument.

Feb-2023: Becton Dickinson and Company reveiled BD Rhapsody HT Xpress System, a new instrument for single-cell multiomics analysis. This product would allow scientists to run high-throughput studies without sacrificing sample integrity potentially accelerating time to discovery across a broad range of disciplines including immunology, genetic disease research, and cancer and chronic disease research.

Jun-2022: Bruker Corporation rolled out the timsTOF HT system, a novel 4th-generation TIMS XR cell and 14-bit digitizer for an even greater dynamic range. The launched product would improve peptide coverage and more accurate quantitation, especially in unbiased 4D plasma and tissue proteomics and epiproteomics.

Mergers & Acquisition

Jan-2022: Bruker Corporation acquired Prolab Instruments GmbH, a Swiss technology company. This acquisition aimed to Augment Multiomics Solutions.

Aug-2021: Illumina, Inc. took over GRAIL, a healthcare company focused on life-saving early detection of multiple cancers. This acquisition aimed to accelerate access and adoption of this life-saving test globally.

Sep-2020: Bruker Corporation took over Canopy Biosciences LLC, a company specializing in high multiplex biomarker imaging for immunology, immuno-oncology, and cell therapy. This acquisition aimed to improve Bruker's portfolios in targeted multi-omics and fluorescence-based imaging techniques.

Geographical Expansions

Aug-2023: Illumina Inc. opened a new facility Illumina Solutions Center in Bengaluru, India. The new facility would support Illumina Inc. to grow the genomics market in India.

Scope of the Study

Market Segments covered in the Report:

By Type

• Bulk Multiomics
• Single-cell Multiomics

By Product & Service

• Product
  • Instruments
  • Consumables
  • Software
• Services

By End-use

• Academic & Research Institutes
• Pharmaceutical & Biotechnology Companies
• Others

By Platform

• Genomics
• Transcriptomics
• Proteomics
• Metabolomics
• Integrated Omics Platforms

By Application

• Cell Biology
• Oncology
• Neurology
• Immunology

By Geography

• North America
  • US
  • Canada
  • Mexico
  • Rest of North America
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
• LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Companies Profiled

• Thermo Fisher Scientific, Inc
• Illumina, Inc.
• Danaher Corporation
• PerkinElmer, Inc.
• Bruker Corporation
• Qiagen N.V.
• Agilent Technologies, Inc.
• BGI Group
• Becton, Dickinson, and Company
• Shimadzu Corporation

Unique Offerings from KBV Research

• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology

• 1.1 Market Definition
• 1.2 Objectives
• 1.3 Market Scope
• 1.4 Segmentation
  • 1.4.1 Global Multiomics Market, by Type
  • 1.4.2 Global Multiomics Market, by Product & Service
  • 1.4.3 Global Multiomics Market, by End-use
  • 1.4.4 Global Multiomics Market, by Platform
  • 1.4.5 Global Multiomics Market, by Application
  • 1.4.6 Global Multiomics Market, by Geography
• 1.5 Methodology for the research

Chapter 2. Market At a Glance

• 2.1 Key Highlights

Chapter 3. Market Overview

• 3.1 Introduction
  • 3.1.1 Overview
    • 3.1.1.1 Market Composition and Scenario
• 3.2 Key Factors Impacting the Market
  • 3.2.1 Market Drivers
  • 3.2.2 Market Restraints

Chapter 4. Competition Analysis - Global

• 4.1 KBV Cardinal Matrix
• 4.2 Recent Industry Wide Strategic Developments
  • 4.2.1 Partnerships, Collaborations and Agreements
  • 4.2.2 Product Launches and Product Expansions
  • 4.2.3 Acquisition and Mergers
  • 4.2.4 Geographical Expansions
• 4.3 Top Winning Strategies
  • 4.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
  • 4.3.2 Key Strategic Move: (Partnerships, Collaborations & Agreements: 2021, Jun - 2023, Mar) Leading Players
• 4.4 Porter's Five Force Analysis

Chapter 5. Global Multiomics Market by Type

• 5.1 Global Bulk Multiomics Market by Region
• 5.2 Global Single-cell Multiomics Market by Region

Chapter 6. Global Multiomics Market by Product & Service

• 6.1 Global Product Market by Region
• 6.2 Global Multiomics Market by Product Type
  • 6.2.1 Global Instruments Market by Region
  • 6.2.2 Global Consumables Market by Region
  • 6.2.3 Global Software Market by Region
• 6.3 Global Services Market by Region

Chapter 7. Global Multiomics Market by End-use

• 7.1 Global Academic & Research Institutes Market by Region
• 7.2 Global Pharmaceutical & Biotechnology Companies Market by Region
• 7.3 Global Others Market by Region

Chapter 8. Global Multiomics Market by Platform

• 8.1 Global Genomics Market by Region
• 8.2 Global Transcriptomics Market by Region
• 8.3 Global Proteomics Market by Region
• 8.4 Global Metabolomics Market by Region
• 8.5 Global Integrated Omics Platforms Market by Region

Chapter 9. Global Multiomics Market by Application

• 9.1 Global Cell Biology Market by Region
• 9.2 Global Oncology Market by Region
• 9.3 Global Neurology Market by Region
• 9.4 Global Immunology Market by Region

Chapter 10. Global Multiomics Market by Region

• 10.1 North America Multiomics Market
  • 10.1.1 North America Multiomics Market by Type
    • 10.1.1.1 North America Bulk Multiomics Market by Region
    • 10.1.1.2 North America Single-cell Multiomics Market by Region
  • 10.1.2 North America Multiomics Market by Product & Service
    • 10.1.2.1 North America Product Market by Country
    • 10.1.2.2 North America Multiomics Market by Product Type
      • 10.1.2.2.1 North America Instruments Market by Country
      • 10.1.2.2.2 North America Consumables Market by Country
      • 10.1.2.2.3 North America Software Market by Country
    • 10.1.2.3 North America Services Market by Country
  • 10.1.3 North America Multiomics Market by End-use
    • 10.1.3.1 North America Academic & Research Institutes Market by Country
    • 10.1.3.2 North America Pharmaceutical & Biotechnology Companies Market by Country
    • 10.1.3.3 North America Others Market by Country
  • 10.1.4 North America Multiomics Market by Platform
    • 10.1.4.1 North America Genomics Market by Country
    • 10.1.4.2 North America Transcriptomics Market by Country
    • 10.1.4.3 North America Proteomics Market by Country
    • 10.1.4.4 North America Metabolomics Market by Country
    • 10.1.4.5 North America Integrated Omics Platforms Market by Country
  • 10.1.5 North America Multiomics Market by Application
    • 10.1.5.1 North America Cell Biology Market by Country
    • 10.1.5.2 North America Oncology Market by Country
    • 10.1.5.3 North America Neurology Market by Country
    • 10.1.5.4 North America Immunology Market by Country
  • 10.1.6 North America Multiomics Market by Country
    • 10.1.6.1 US Multiomics Market
      • 10.1.6.1.1 US Multiomics Market by Type
      • 10.1.6.1.2 US Multiomics Market by Product & Service
      • 10.1.6.1.3 US Multiomics Market by End-use
      • 10.1.6.1.4 US Multiomics Market by Platform
      • 10.1.6.1.5 US Multiomics Market by Application
    • 10.1.6.2 Canada Multiomics Market
      • 10.1.6.2.1 Canada Multiomics Market by Type
      • 10.1.6.2.2 Canada Multiomics Market by Product & Service
      • 10.1.6.2.3 Canada Multiomics Market by End-use
      • 10.1.6.2.4 Canada Multiomics Market by Platform
      • 10.1.6.2.5 Canada Multiomics Market by Application
    • 10.1.6.3 Mexico Multiomics Market
      • 10.1.6.3.1 Mexico Multiomics Market by Type
      • 10.1.6.3.2 Mexico Multiomics Market by Product & Service
      • 10.1.6.3.3 Mexico Multiomics Market by End-use
      • 10.1.6.3.4 Mexico Multiomics Market by Platform
      • 10.1.6.3.5 Mexico Multiomics Market by Application
    • 10.1.6.4 Rest of North America Multiomics Market
      • 10.1.6.4.1 Rest of North America Multiomics Market by Type
      • 10.1.6.4.2 Rest of North America Multiomics Market by Product & Service
      • 10.1.6.4.3 Rest of North America Multiomics Market by End-use
      • 10.1.6.4.4 Rest of North America Multiomics Market by Platform
      • 10.1.6.4.5 Rest of North America Multiomics Market by Application
• 10.2 Europe Multiomics Market
  • 10.2.1 Europe Multiomics Market by Type
    • 10.2.1.1 Europe Bulk Multiomics Market by Country
    • 10.2.1.2 Europe Single-cell Multiomics Market by Country
  • 10.2.2 Europe Multiomics Market by Product & Service
    • 10.2.2.1 Europe Product Market by Country
    • 10.2.2.2 Europe Multiomics Market by Product Type
      • 10.2.2.2.1 Europe Instruments Market by Country
      • 10.2.2.2.2 Europe Consumables Market by Country
      • 10.2.2.2.3 Europe Software Market by Country
    • 10.2.2.3 Europe Services Market by Country
  • 10.2.3 Europe Multiomics Market by End-use
    • 10.2.3.1 Europe Academic & Research Institutes Market by Country
    • 10.2.3.2 Europe Pharmaceutical & Biotechnology Companies Market by Country
    • 10.2.3.3 Europe Others Market by Country
  • 10.2.4 Europe Multiomics Market by Platform
    • 10.2.4.1 Europe Genomics Market by Country
    • 10.2.4.2 Europe Transcriptomics Market by Country
    • 10.2.4.3 Europe Proteomics Market by Country
    • 10.2.4.4 Europe Metabolomics Market by Country
    • 10.2.4.5 Europe Integrated Omics Platforms Market by Country
  • 10.2.5 Europe Multiomics Market by Application
    • 10.2.5.1 Europe Cell Biology Market by Country
    • 10.2.5.2 Europe Oncology Market by Country
    • 10.2.5.3 Europe Neurology Market by Country
    • 10.2.5.4 Europe Immunology Market by Country
  • 10.2.6 Europe Multiomics Market by Country
    • 10.2.6.1 Germany Multiomics Market
      • 10.2.6.1.1 Germany Multiomics Market by Type
      • 10.2.6.1.2 Germany Multiomics Market by Product & Service
      • 10.2.6.1.3 Germany Multiomics Market by End-use
      • 10.2.6.1.4 Germany Multiomics Market by Platform
      • 10.2.6.1.5 Germany Multiomics Market by Application
    • 10.2.6.2 UK Multiomics Market
      • 10.2.6.2.1 UK Multiomics Market by Type
      • 10.2.6.2.2 UK Multiomics Market by Product & Service
      • 10.2.6.2.3 UK Multiomics Market by End-use
      • 10.2.6.2.4 UK Multiomics Market by Platform
      • 10.2.6.2.5 UK Multiomics Market by Application
    • 10.2.6.3 France Multiomics Market
      • 10.2.6.3.1 France Multiomics Market by Type
      • 10.2.6.3.2 France Multiomics Market by Product & Service
      • 10.2.6.3.3 France Multiomics Market by End-use
      • 10.2.6.3.4 France Multiomics Market by Platform
      • 10.2.6.3.5 France Multiomics Market by Application
    • 10.2.6.4 Russia Multiomics Market
      • 10.2.6.4.1 Russia Multiomics Market by Type
      • 10.2.6.4.2 Russia Multiomics Market by Product & Service
      • 10.2.6.4.3 Russia Multiomics Market by End-use
      • 10.2.6.4.4 Russia Multiomics Market by Platform
      • 10.2.6.4.5 Russia Multiomics Market by Application
    • 10.2.6.5 Spain Multiomics Market
      • 10.2.6.5.1 Spain Multiomics Market by Type
      • 10.2.6.5.2 Spain Multiomics Market by Product & Service
      • 10.2.6.5.3 Spain Multiomics Market by End-use
      • 10.2.6.5.4 Spain Multiomics Market by Platform
      • 10.2.6.5.5 Spain Multiomics Market by Application
    • 10.2.6.6 Italy Multiomics Market
      • 10.2.6.6.1 Italy Multiomics Market by Type
      • 10.2.6.6.2 Italy Multiomics Market by Product & Service
      • 10.2.6.6.3 Italy Multiomics Market by End-use
      • 10.2.6.6.4 Italy Multiomics Market by Platform
      • 10.2.6.6.5 Italy Multiomics Market by Application
    • 10.2.6.7 Rest of Europe Multiomics Market
      • 10.2.6.7.1 Rest of Europe Multiomics Market by Type
      • 10.2.6.7.2 Rest of Europe Multiomics Market by Product & Service
      • 10.2.6.7.3 Rest of Europe Multiomics Market by End-use
      • 10.2.6.7.4 Rest of Europe Multiomics Market by Platform
      • 10.2.6.7.5 Rest of Europe Multiomics Market by Application
• 10.3 Asia Pacific Multiomics Market
  • 10.3.1 Asia Pacific Multiomics Market by Type
    • 10.3.1.1 Asia Pacific Bulk Multiomics Market by Country
    • 10.3.1.2 Asia Pacific Single-cell Multiomics Market by Country
  • 10.3.2 Asia Pacific Multiomics Market by Product & Service
    • 10.3.2.1 Asia Pacific Product Market by Country
    • 10.3.2.2 Asia Pacific Multiomics Market by Product Type
      • 10.3.2.2.1 Asia Pacific Instruments Market by Country
      • 10.3.2.2.2 Asia Pacific Consumables Market by Country
      • 10.3.2.2.3 Asia Pacific Software Market by Country
    • 10.3.2.3 Asia Pacific Services Market by Country
  • 10.3.3 Asia Pacific Multiomics Market by End-use
    • 10.3.3.1 Asia Pacific Academic & Research Institutes Market by Country
    • 10.3.3.2 Asia Pacific Pharmaceutical & Biotechnology Companies Market by Country
    • 10.3.3.3 Asia Pacific Others Market by Country
  • 10.3.4 Asia Pacific Multiomics Market by Platform
    • 10.3.4.1 Asia Pacific Genomics Market by Country
    • 10.3.4.2 Asia Pacific Transcriptomics Market by Country
    • 10.3.4.3 Asia Pacific Proteomics Market by Country
    • 10.3.4.4 Asia Pacific Metabolomics Market by Country
    • 10.3.4.5 Asia Pacific Integrated Omics Platforms Market by Country
  • 10.3.5 Asia Pacific Multiomics Market by Application
    • 10.3.5.1 Asia Pacific Cell Biology Market by Country
    • 10.3.5.2 Asia Pacific Oncology Market by Country
    • 10.3.5.3 Asia Pacific Neurology Market by Country
    • 10.3.5.4 Asia Pacific Immunology Market by Country
  • 10.3.6 Asia Pacific Multiomics Market by Country
    • 10.3.6.1 China Multiomics Market
      • 10.3.6.1.1 China Multiomics Market by Type
      • 10.3.6.1.2 China Multiomics Market by Product & Service
      • 10.3.6.1.3 China Multiomics Market by End-use
      • 10.3.6.1.4 China Multiomics Market by Platform
      • 10.3.6.1.5 China Multiomics Market by Application
    • 10.3.6.2 Japan Multiomics Market
      • 10.3.6.2.1 Japan Multiomics Market by Type
      • 10.3.6.2.2 Japan Multiomics Market by Product & Service
      • 10.3.6.2.3 Japan Multiomics Market by End-use
      • 10.3.6.2.4 Japan Multiomics Market by Platform
      • 10.3.6.2.5 Japan Multiomics Market by Application
    • 10.3.6.3 India Multiomics Market
      • 10.3.6.3.1 India Multiomics Market by Type
      • 10.3.6.3.2 India Multiomics Market by Product & Service
      • 10.3.6.3.3 India Multiomics Market by End-use
      • 10.3.6.3.4 India Multiomics Market by Platform
      • 10.3.6.3.5 India Multiomics Market by Application
    • 10.3.6.4 South Korea Multiomics Market
      • 10.3.6.4.1 South Korea Multiomics Market by Type
      • 10.3.6.4.2 South Korea Multiomics Market by Product & Service
      • 10.3.6.4.3 South Korea Multiomics Market by End-use
      • 10.3.6.4.4 South Korea Multiomics Market by Platform
      • 10.3.6.4.5 South Korea Multiomics Market by Application
    • 10.3.6.5 Singapore Multiomics Market
      • 10.3.6.5.1 Singapore Multiomics Market by Type
      • 10.3.6.5.2 Singapore Multiomics Market by Product & Service
      • 10.3.6.5.3 Singapore Multiomics Market by End-use
      • 10.3.6.5.4 Singapore Multiomics Market by Platform
      • 10.3.6.5.5 Singapore Multiomics Market by Application
    • 10.3.6.6 Malaysia Multiomics Market
      • 10.3.6.6.1 Malaysia Multiomics Market by Type
      • 10.3.6.6.2 Malaysia Multiomics Market by Product & Service
      • 10.3.6.6.3 Malaysia Multiomics Market by End-use
      • 10.3.6.6.4 Malaysia Multiomics Market by Platform
      • 10.3.6.6.5 Malaysia Multiomics Market by Application
    • 10.3.6.7 Rest of Asia Pacific Multiomics Market
      • 10.3.6.7.1 Rest of Asia Pacific Multiomics Market by Type
      • 10.3.6.7.2 Rest of Asia Pacific Multiomics Market by Product & Service
      • 10.3.6.7.3 Rest of Asia Pacific Multiomics Market by End-use
      • 10.3.6.7.4 Rest of Asia Pacific Multiomics Market by Platform
      • 10.3.6.7.5 Rest of Asia Pacific Multiomics Market by Application
• 10.4 LAMEA Multiomics Market
  • 10.4.1 LAMEA Multiomics Market by Type
    • 10.4.1.1 LAMEA Bulk Multiomics Market by Country
    • 10.4.1.2 LAMEA Single-cell Multiomics Market by Country
  • 10.4.2 LAMEA Multiomics Market by Product & Service
    • 10.4.2.1 LAMEA Product Market by Country
    • 10.4.2.2 LAMEA Multiomics Market by Product Type
      • 10.4.2.2.1 LAMEA Instruments Market by Country
      • 10.4.2.2.2 LAMEA Consumables Market by Country
      • 10.4.2.2.3 LAMEA Software Market by Country
    • 10.4.2.3 LAMEA Services Market by Country
  • 10.4.3 LAMEA Multiomics Market by End-use
    • 10.4.3.1 LAMEA Academic & Research Institutes Market by Country
    • 10.4.3.2 LAMEA Pharmaceutical & Biotechnology Companies Market by Country
    • 10.4.3.3 LAMEA Others Market by Country
  • 10.4.4 LAMEA Multiomics Market by Platform
    • 10.4.4.1 LAMEA Genomics Market by Country
    • 10.4.4.2 LAMEA Transcriptomics Market by Country
    • 10.4.4.3 LAMEA Proteomics Market by Country
    • 10.4.4.4 LAMEA Metabolomics Market by Country
    • 10.4.4.5 LAMEA Integrated Omics Platforms Market by Country
  • 10.4.5 LAMEA Multiomics Market by Application
    • 10.4.5.1 LAMEA Cell Biology Market by Country
    • 10.4.5.2 LAMEA Oncology Market by Country
    • 10.4.5.3 LAMEA Neurology Market by Country
    • 10.4.5.4 LAMEA Immunology Market by Country
  • 10.4.6 LAMEA Multiomics Market by Country
    • 10.4.6.1 Brazil Multiomics Market
      • 10.4.6.1.1 Brazil Multiomics Market by Type
      • 10.4.6.1.2 Brazil Multiomics Market by Product & Service
      • 10.4.6.1.3 Brazil Multiomics Market by End-use
      • 10.4.6.1.4 Brazil Multiomics Market by Platform
      • 10.4.6.1.5 Brazil Multiomics Market by Application
    • 10.4.6.2 Argentina Multiomics Market
      • 10.4.6.2.1 Argentina Multiomics Market by Type
      • 10.4.6.2.2 Argentina Multiomics Market by Product & Service
      • 10.4.6.2.3 Argentina Multiomics Market by End-use
      • 10.4.6.2.4 Argentina Multiomics Market by Platform
      • 10.4.6.2.5 Argentina Multiomics Market by Application
    • 10.4.6.3 UAE Multiomics Market
      • 10.4.6.3.1 UAE Multiomics Market by Type
      • 10.4.6.3.2 UAE Multiomics Market by Product & Service
      • 10.4.6.3.3 UAE Multiomics Market by End-use
      • 10.4.6.3.4 UAE Multiomics Market by Platform
      • 10.4.6.3.5 UAE Multiomics Market by Application
    • 10.4.6.4 Saudi Arabia Multiomics Market
      • 10.4.6.4.1 Saudi Arabia Multiomics Market by Type
      • 10.4.6.4.2 Saudi Arabia Multiomics Market by Product & Service
      • 10.4.6.4.3 Saudi Arabia Multiomics Market by End-use
      • 10.4.6.4.4 Saudi Arabia Multiomics Market by Platform
      • 10.4.6.4.5 Saudi Arabia Multiomics Market by Application
    • 10.4.6.5 South Africa Multiomics Market
      • 10.4.6.5.1 South Africa Multiomics Market by Type
      • 10.4.6.5.2 South Africa Multiomics Market by Product & Service
      • 10.4.6.5.3 South Africa Multiomics Market by End-use
      • 10.4.6.5.4 South Africa Multiomics Market by Platform
      • 10.4.6.5.5 South Africa Multiomics Market by Application
    • 10.4.6.6 Nigeria Multiomics Market
      • 10.4.6.6.1 Nigeria Multiomics Market by Type
      • 10.4.6.6.2 Nigeria Multiomics Market by Product & Service
      • 10.4.6.6.3 Nigeria Multiomics Market by End-use
      • 10.4.6.6.4 Nigeria Multiomics Market by Platform
      • 10.4.6.6.5 Nigeria Multiomics Market by Application
    • 10.4.6.7 Rest of LAMEA Multiomics Market
      • 10.4.6.7.1 Rest of LAMEA Multiomics Market by Type
      • 10.4.6.7.2 Rest of LAMEA Multiomics Market by Product & Service
      • 10.4.6.7.3 Rest of LAMEA Multiomics Market by Product Type
      • 10.4.6.7.4 Rest of LAMEA Multiomics Market by End-use
      • 10.4.6.7.5 Rest of LAMEA Multiomics Market by Platform
      • 10.4.6.7.6 Rest of LAMEA Multiomics Market by Application

Chapter 11. Company Profiles

• 11.1 Thermo Fisher Scientific, Inc.
  • 11.1.1 Company Overview
  • 11.1.2 Financial Analysis
  • 11.1.3 Segmental and Regional Analysis
  • 11.1.4 Research & Development Expenses
  • 11.1.5 SWOT Analysis
• 11.2 Illumina, Inc.
  • 11.2.1 Company Overview
  • 11.2.2 Financial Analysis
  • 11.2.3 Segmental and Regional Analysis
  • 11.2.4 Research & Development Expense
  • 11.2.5 Recent strategies and developments:
    • 11.2.5.1 Partnerships, Collaborations, and Agreements:
    • 11.2.5.2 Product Launches and Product Expansions:
    • 11.2.5.3 Acquisition and Mergers:
    • 11.2.5.4 Geographical Expansions:
  • 11.2.6 SWOT Analysis
• 11.3 Danaher Corporation
  • 11.3.1 Company Overview
  • 11.3.2 Financial Analysis
  • 11.3.3 Segmental and Regional Analysis
  • 11.3.4 Research & Development Expense
  • 11.3.5 SWOT Analysis
• 11.4 PerkinElmer, Inc.
  • 11.4.1 Company Overview
  • 11.4.2 Financial Analysis
  • 11.4.3 Segmental and Regional Analysis
  • 11.4.4 Research & Development Expense
  • 11.4.5 SWOT Analysis
• 11.5 Bruker Corporation
  • 11.5.1 Company Overview
  • 11.5.2 Financial Analysis
  • 11.5.3 Segmental and Regional Analysis
  • 11.5.4 Research & Development Expense
  • 11.5.5 Recent strategies and developments:
    • 11.5.5.1 Partnerships, Collaborations, and Agreements:
    • 11.5.5.2 Product Launches and Product Expansions:
    • 11.5.5.3 Acquisition and Mergers:
  • 11.5.6 SWOT Analysis
• 11.6 Qiagen N.V.
  • 11.6.1 Company Overview
  • 11.6.2 Financial Analysis
  • 11.6.3 Regional Analysis
  • 11.6.4 Research & Development Expense
  • 11.6.5 SWOT Analysis
• 11.7 Agilent Technologies, Inc.
  • 11.7.1 Company Overview
  • 11.7.2 Financial Analysis
  • 11.7.3 Segmental and Regional Analysis
  • 11.7.4 Research & Development Expense
  • 11.7.5 Recent strategies and developments:
    • 11.7.5.1 Partnerships, Collaborations, and Agreements:
  • 11.7.6 SWOT Analysis
• 11.8 BGI Group
  • 11.8.1 Company Overview
  • 11.8.2 Recent strategies and developments:
    • 11.8.2.1 Partnerships, Collaborations, and Agreements:
  • 11.8.3 SWOT Analysis
• 11.9 Becton, Dickinson, and Company
  • 11.9.1 Company Overview
  • 11.9.2 Financial Analysis
  • 11.9.3 Segmental and Regional Analysis
  • 11.9.4 Research & Development Expense
    • 11.9.4.1 Product Launches and Product Expansions:
  • 11.9.5 SWOT Analysis
• 11.10. Shimadzu Corporation
  • 11.10.1 Company Overview
  • 11.10.2 Financial Analysis
  • 11.10.3 Segmental and Regional Analysis
  • 11.10.4 Research & Development Expense
  • 11.10.5 SWOT Analysis

Chapter 12. Winning imperative of Multiomics Market